Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.

Lantuejoul S, Damotte D, Hofman V, Adam J.

J Thorac Dis. 2019 Jan;11(Suppl 1):S89-S101. doi: 10.21037/jtd.2018.12.103. Review.

2.

Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors.

Mansuet-Lupo A, Barritault M, Alifano M, Janet-Vendroux A, Zarmaev M, Biton J, Velut Y, Le Hay C, Cremer I, Régnard JF, Fournel L, Rance B, Wislez M, Laurent-Puig P, Herbst R, Damotte D, Blons H.

J Thorac Oncol. 2019 Feb 2. pii: S1556-0864(19)30093-0. doi: 10.1016/j.jtho.2019.01.017. [Epub ahead of print]

PMID:
30721797
3.

T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization.

Belhadj M, Mansour D, Kaltenbach S, Deau-Fischer B, Franchi P, Tamburini J, Chapuis N, Damotte D, Kosmider O, Burroni B, Bouscary D.

Haematologica. 2019 Mar;104(3):e117-e120. doi: 10.3324/haematol.2018.205542. Epub 2018 Dec 20. No abstract available.

4.

Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells.

Dajon M, Iribarren K, Petitprez F, Marmier S, Lupo A, Gillard M, Ouakrim H, Victor N, Vincenzo DB, Joubert PE, Kepp O, Kroemer G, Alifano M, Damotte D, Cremer I.

Oncoimmunology. 2018 Oct 11;8(1):e1505174. doi: 10.1080/2162402X.2018.1505174. eCollection 2019.

5.

Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.

Sarkozy C, Copie-Bergman C, Damotte D, Ben-Neriah S, Burroni B, Cornillon J, Lemal R, Golfier C, Fabiani B, Chassagne-Clément C, Parrens M, Herbaux C, Xerri L, Bossard C, Laurent C, Cheminant M, Cartron G, Cabecadas J, Molina T, Salles G, Steidl C, Ghesquières H, Mottok A, Traverse-Glehen A.

Am J Surg Pathol. 2019 Mar;43(3):341-351. doi: 10.1097/PAS.0000000000001198.

PMID:
30540571
6.

Synchronous Oligometastatic Lung Cancer Deserves a Dedicated Management.

Loi M, Mazzella A, Mansuet-Lupo A, Bobbio A, Canny E, Magdeleinat P, Régnard JF, Damotte D, Trédaniel J, Alifano M.

Ann Thorac Surg. 2018 Nov 23. pii: S0003-4975(18)31681-3. doi: 10.1016/j.athoracsur.2018.10.029. [Epub ahead of print]

PMID:
30476480
7.

Lung Involvement in Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma.

Saade A, Carton E, Mansuet-Lupo A, Jouffroy R, Damotte D, Yera H, Revel MP, Goldwasser F.

Emerg Infect Dis. 2018 Dec;24(12):2375-2378. doi: 10.3201/eid2412.180355.

8.

High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer.

Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, Sirab N, Barry Delongchamps N, Zerbib M, Sibony M, Allory Y, Damotte D, Bieche I.

Mol Cancer Res. 2019 Feb;17(2):469-475. doi: 10.1158/1541-7786.MCR-18-0363. Epub 2018 Nov 6.

PMID:
30401719
9.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M.

Rev Pneumol Clin. 2018 Oct;74(5):327-338. doi: 10.1016/j.pneumo.2018.09.013. Epub 2018 Oct 19. Review. French.

PMID:
30343945
10.

[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].

Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D.

Rev Pneumol Clin. 2018 Oct;74(5):339-350. doi: 10.1016/j.pneumo.2018.09.010. Epub 2018 Oct 15. Review. French.

PMID:
30337201
11.

[Malignant pleural mesothelioma: The role of surgery].

Fournel L, Janet-Vendroux A, Canny-Hamelin E, Mansuet-Lupo A, Guinet C, Bobbio A, Damotte D, Alifano M.

Rev Pneumol Clin. 2018 Oct;74(5):351-358. doi: 10.1016/j.pneumo.2018.09.006. Epub 2018 Oct 11. Review. French.

PMID:
30316650
12.

Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.

Lheure C, Hoffmann C, Kramkimel N, Plée J, Franck N, Vanhaecke C, Goldman-Lévy G, Bataillon G, Damotte D, Dupin N, Aractingi S, Grange F, Guégan S.

Acta Derm Venereol. 2019 Jan 1;99(1):107-108. doi: 10.2340/00015555-3028. No abstract available.

13.

[Analysis of immune microenvironment by multiplex immunohistochemistry in locally advanced non-small cell lung cancer: Principles and perspectives].

Boulle G, Velut Y, Boni A, Lupo A, Alifano M, Trédaniel J, Giraud P, Damotte D.

Cancer Radiother. 2018 Oct;22(6-7):688-693. doi: 10.1016/j.canrad.2018.07.031. Epub 2018 Aug 18. Review. French.

PMID:
30131267
14.

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D.

Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.

PMID:
29764856
15.

Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.

Braud VM, Biton J, Becht E, Knockaert S, Mansuet-Lupo A, Cosson E, Damotte D, Alifano M, Validire P, Anjuère F, Cremer I, Girard N, Gossot D, Seguin-Givelet A, Dieu-Nosjean MC, Germain C.

Oncoimmunology. 2018 Jan 29;7(5):e1423184. doi: 10.1080/2162402X.2017.1423184. eCollection 2018.

16.

Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.

Birsen R, Blanc E, Willems L, Burroni B, Legoff M, Le Ray E, Pilorge S, Salah S, Quentin A, Deau B, Franchi P, Vignon M, Mabille L, Nguyen C, Kirova Y, Varlet P, Edjlali M, Dezamis E, Hoang-Xuan K, Soussain C, Houillier C, Damotte D, Pallud J, Bouscary D, Tamburini J.

Oncotarget. 2018 Mar 30;9(24):16822-16831. doi: 10.18632/oncotarget.24706. eCollection 2018 Mar 30.

17.

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.

Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Guérin M, Biton J, Ouakrim H, Régnier F, Lupo A, Alifano M, Damotte D, Donnadieu E.

Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E4041-E4050. doi: 10.1073/pnas.1720948115. Epub 2018 Apr 9.

18.

[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].

Lantuejoul S, Adam J, Girard N, Duruisseaux M, Mansuet-Lupo A, Cazes A, Rouquette I, Gibault L, Garcia S, Antoine M, Vignaud JM, Galateau-Sallé F, Sagan C, Badoual C, Penault-Llorca F, Damotte D; pour le groupe pathologistes thoraciques de valorisation de l’expertise, de la recherche et de l’innovation (PATTERN). Fondation Synergie Lyon Cancer.

Ann Pathol. 2018 Apr;38(2):110-125. doi: 10.1016/j.annpat.2018.01.007. Epub 2018 Mar 21. French.

PMID:
29571563
19.

Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.

Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H, Halpin R, Creasy T, Bantsimba-Malanda C, Arrondeau J, Goldwasser F, Boudou-Rouquette P, Fournel L, Roche N, Burgel PR, Goc J, Devi-Marulkar P, Germain C, Dieu-Nosjean MC, Cremer I, Herbst R, Damotte D.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940. doi: 10.1164/rccm.201706-1110OC.

PMID:
29518341
20.

Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells.

Bennett Saidu NE, Bretagne M, Mansuet AL, Just PA, Leroy K, Cerles O, Chouzenoux S, Nicco C, Damotte D, Alifano M, Borghese B, Goldwasser F, Batteux F, Alexandre J.

Oncotarget. 2018 Jan 10;9(10):9088-9099. doi: 10.18632/oncotarget.24144. eCollection 2018 Feb 6.

21.

Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.

Birsen R, Willems L, Pallud J, Blanc E, Burroni B, Legoff M, Le Ray E, Pilorge S, Deau B, Franchi P, Vignon M, Kirova Y, Edjlali M, Houillier C, Soussain C, Varlet P, Dezamis E, Damotte D, Bouscary D, Tamburini J.

Haematologica. 2018 Jul;103(7):e296-e299. doi: 10.3324/haematol.2017.185843. Epub 2018 Feb 22. No abstract available.

22.

Ex Vivo Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy.

Peranzoni E, Bougherara H, Barrin S, Mansuet-Lupo A, Alifano M, Damotte D, Donnadieu E.

J Vis Exp. 2017 Dec 27;(130). doi: 10.3791/55709.

23.

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.

Adam J, Le Stang N, Rouquette I, Cazes A, Badoual C, Pinot-Roussel H, Tixier L, Danel C, Damiola F, Damotte D, Penault-Llorca F, Lantuéjoul S.

Ann Oncol. 2018 Apr 1;29(4):953-958. doi: 10.1093/annonc/mdy014.

PMID:
29351573
24.

The Human Penis Is a Genuine Immunological Effector Site.

Sennepin A, Real F, Duvivier M, Ganor Y, Henry S, Damotte D, Revol M, Cristofari S, Bomsel M.

Front Immunol. 2017 Dec 14;8:1732. doi: 10.3389/fimmu.2017.01732. eCollection 2017.

25.

Anaplastic Kaposi's sarcoma: 5 cases of a rare and aggressive type of Kaposi's sarcoma.

Chapalain M, Goldman-Lévy G, Kramkimel N, Carlotti A, Franck N, Lheure C, Audard V, Avril MF, Marcelin AG, Damotte D, Terris B, Aractingi S, Dupin N.

Ann Dermatol Venereol. 2018 Jan;145(1):21-28. doi: 10.1016/j.annder.2017.09.593. Epub 2017 Dec 28.

PMID:
29290414
26.

Tumor Necrosis Factor-Alpha Targeting Can Protect against Arthritis with Low Sensitization to Infection.

Belmellat N, Semerano L, Segueni N, Damotte D, Decker P, Ryffel B, Quesniaux V, Boissier MC, Assier E.

Front Immunol. 2017 Nov 14;8:1533. doi: 10.3389/fimmu.2017.01533. eCollection 2017.

27.

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Le Goux C, Vacher S, Pignot G, Sibony M, Barry Delongchamps N, Terris B, Piaggio E, Zerbib M, Damotte D, Bieche I.

Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.

28.

Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.

Lococo F, Torricelli F, Rossi G, Alifano M, Damotte D, Rapicetta C, Tamagnini I, Cavazza A, Piana S, Galeone C, Paci M, Ciarrocchi A.

Lung Cancer. 2017 Nov;113:93-101. doi: 10.1016/j.lungcan.2017.09.009. Epub 2017 Sep 18.

PMID:
29110857
29.

Thoracic Endometriosis Syndrome Other Than Pneumothorax: Clinical and Pathological Findings.

Bobbio A, Canny E, Mansuet Lupo A, Lococo F, Legras A, Magdeleinat P, Regnard JF, Gompel A, Damotte D, Alifano M.

Ann Thorac Surg. 2017 Dec;104(6):1865-1871. doi: 10.1016/j.athoracsur.2017.06.049. Epub 2017 Oct 17.

PMID:
29054304
30.

Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study-The Importance of Pathological N Status, More Than We Thought.

Cusumano G, Fournel L, Strano S, Damotte D, Charpentier MC, Galia A, Terminella A, Nicolosi M, Regnard JF, Alifano M.

Lung. 2017 Dec;195(6):789-798. doi: 10.1007/s00408-017-0056-8. Epub 2017 Oct 11.

PMID:
29022070
31.

In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide.

Remark R, Merghoub T, Grabe N, Litjens G, Damotte D, Wolchok JD, Merad M, Gnjatic S.

Sci Immunol. 2016 Jul 14;1(1):aaf6925. doi: 10.1126/sciimmunol.aaf6925. Epub 2016 Jun 23.

PMID:
28783673
32.

Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Franck N, Arrondeau J, Guégan S, Mansuet-Lupo A, Alexandre J, Damotte D, Avril MF, Dupin N, Aractingi S.

Invest New Drugs. 2017 Dec;35(6):842-847. doi: 10.1007/s10637-017-0476-6. Epub 2017 May 31.

PMID:
28569347
33.

Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.

Prieux-Klotz C, Dior M, Damotte D, Dreanic J, Brieau B, Brezault C, Abitbol V, Chaussade S, Coriat R.

Target Oncol. 2017 Jun;12(3):301-308. doi: 10.1007/s11523-017-0495-4.

PMID:
28540478
34.

Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.

Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T, Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picquenot JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, Salles G, Molina TJ, Delsol G, Brousset P, Gaulard P.

J Clin Oncol. 2017 Jun 20;35(18):2008-2017. doi: 10.1200/JCO.2016.71.2083. Epub 2017 May 1.

PMID:
28459613
35.

Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis.

Frija-Masson J, Martin C, Regard L, Lothe MN, Touqui L, Durand A, Lucas B, Damotte D, Alifano M, Fajac I, Burgel PR.

Eur Respir J. 2017 Apr 26;49(4). pii: 1601873. doi: 10.1183/13993003.01873-2016. Print 2017 Apr.

36.

The HIV-1 viral synapse signals human foreskin keratinocytes to secrete thymic stromal lymphopoietin facilitating HIV-1 foreskin entry.

Zhou Z, Xu L, Sennepin A, Federici C, Ganor Y, Tudor D, Damotte D, Barry Delongchamps N, Zerbib M, Bomsel M.

Mucosal Immunol. 2018 Jan;11(1):158-171. doi: 10.1038/mi.2017.23. Epub 2017 Apr 26.

PMID:
28443609
37.

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.

Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié JJ, Laurent C.

Oncotarget. 2017 Jul 4;8(27):44960-44975. doi: 10.18632/oncotarget.16680. Review.

38.

Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.

Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G.

Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11.

PMID:
28291636
39.

Correlation between radiological and pathological features of operated ground glass nodules.

Fournel L, Etienne H, Mansuet Lupo A, Damotte D, Rouquette A, Revel MP, Guinet C, Alifano M, Regnard JF.

Eur J Cardiothorac Surg. 2017 Feb 1;51(2):248-254. doi: 10.1093/ejcts/ezw294. No abstract available.

PMID:
28186249
40.

[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].

Duruisseaux M, Rouquette I, Adam J, Cortot A, Cazes A, Gibault L, Damotte D, Lantuejoul S.

Ann Pathol. 2017 Feb;37(1):61-78. doi: 10.1016/j.annpat.2016.12.009. Epub 2017 Feb 3. Review. French.

PMID:
28162296
41.

[Immune-checkpoint and hemopathies].

Burroni B, Broudin C, Damotte D, Laurent C.

Ann Pathol. 2017 Feb;37(1):101-110. doi: 10.1016/j.annpat.2016.12.005. Epub 2017 Feb 1. Review. French.

PMID:
28161001
42.

Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients.

Remark R, Lupo A, Alifano M, Biton J, Ouakrim H, Stefani A, Cremer I, Goc J, Régnard JF, Dieu-Nosjean MC, Damotte D.

Oncoimmunology. 2016 Dec 8;5(12):e1255394. doi: 10.1080/2162402X.2016.1255394. eCollection 2016.

43.

Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association.

Sarkozy C, Molina T, Ghesquières H, Michallet AS, Dupuis J, Damotte D, Morsschauser F, Parrens M, Martin L, Dartigues P, Stamatoullas A, Hirsch P, Fabiani B, Bouabdallah K, da Silva MG, Maerevoet M, Laurent C, Coiffier B, Salles G, Traverse-Glehen A.

Haematologica. 2017 Jan;102(1):150-159. doi: 10.3324/haematol.2016.152256. Epub 2016 Oct 6.

44.

Body Mass Index and Total Psoas Area Affect Outcomes in Patients Undergoing Pneumonectomy for Cancer.

Hervochon R, Bobbio A, Guinet C, Mansuet-Lupo A, Rabbat A, Régnard JF, Roche N, Damotte D, Iannelli A, Alifano M.

Ann Thorac Surg. 2017 Jan;103(1):287-295. doi: 10.1016/j.athoracsur.2016.06.077. Epub 2016 Sep 19.

PMID:
27659598
45.

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.

Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, Dubois S, Sola B, Ochmann M, Lemonnier F, Viailly PJ, Bertrand P, Maingonnat C, Traverse-Glehen A, Gaulard P, Damotte D, Delarue R, Haioun C, Argueta C, Landesman Y, Salles G, Jais JP, Figeac M, Copie-Bergman C, Molina TJ, Picquenot JM, Cornic M, Fest T, Milpied N, Lemasle E, Stamatoullas A, Moeller P, Dyer MJ, Sundstrom C, Bastard C, Tilly H, Leroy K.

Am J Hematol. 2016 Sep;91(9):923-30. doi: 10.1002/ajh.24451. Epub 2016 Jul 4.

46.

Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations.

Mansuet-Lupo A, Alifano M, Pécuchet N, Biton J, Becht E, Goc J, Germain C, Ouakrim H, Régnard JF, Cremer I, Laurent-Puig P, Dieu-Nosjean MC, Blons H, Damotte D.

Am J Respir Crit Care Med. 2016 Dec 1;194(11):1403-1412.

PMID:
27299180
47.

Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.

Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, Lupo A, Fridman WH, Dieu-Nosjean MC, Kroemer G, Sautès-Fridman C, Cremer I.

Cancer Res. 2016 Apr 1;76(7):1746-56. doi: 10.1158/0008-5472.CAN-15-1142. Epub 2016 Feb 3.

48.

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.

Pécuchet N, Laurent-Puig P, Mansuet-Lupo A, Legras A, Alifano M, Pallier K, Didelot A, Gibault L, Danel C, Just PA, Riquet M, Le Pimpec-Barthes F, Damotte D, Fabre E, Blons H.

Oncotarget. 2017 Apr 4;8(14):23831-23840. doi: 10.18632/oncotarget.6379.

49.

A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality.

Zhu W, Germain C, Liu Z, Sebastian Y, Devi P, Knockaert S, Brohawn P, Lehmann K, Damotte D, Validire P, Yao Y, Valge-Archer V, Hammond SA, Dieu-Nosjean MC, Higgs BW.

Oncoimmunology. 2015 Jun 1;4(12):e1051922. eCollection 2015 Dec.

50.

Real-Time Imaging of Resident T Cells in Human Lung and Ovarian Carcinomas Reveals How Different Tumor Microenvironments Control T Lymphocyte Migration.

Bougherara H, Mansuet-Lupo A, Alifano M, Ngô C, Damotte D, Le Frère-Belda MA, Donnadieu E, Peranzoni E.

Front Immunol. 2015 Oct 12;6:500. doi: 10.3389/fimmu.2015.00500. eCollection 2015.

Supplemental Content

Loading ...
Support Center